Alkermes plc Stock News

ANIK vs. ALKS: Which Stock Is the Better Value Option?

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Equities analysts expect Alkermes Plc (NASDAQ:ALKS) to post $225.02 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Alkermes’ earnings, with the low

The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week,...

BidaskClub upgraded shares of Alkermes (NASDAQ:ALKS) from a sell rating to a hold rating in a report issued on Tuesday morning, BidAskClub reports. Other research analysts also recently issued reports

Pune, April 24, 2020 -- The global opioid use disorder market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period..

Gainers • Immunomedics, Inc. (NASDAQ:IMMU) stock rose 31.29% to $28.87 during Thursday's pre-market session. The most recent rating by H.C. Wainwright, on Apr 23, is at...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company's first quarter 2020 financial resu

Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 Ways to Lead with Heart During Times of Uncertainty and Change, a complimentary 60-minute webinar for people leaders confronting the impacts of COVID-19, is returning in May. The webinar, led by Dav

Alkermes' candidate ALKS 4230 shows anti-tumor efficacy in publication ALKS

Alkermes plc (Nasdaq: ALKS) today announced the publication of preclinical data demonstrating the selectivity and anti-tumor efficacy of its investigational, immunotherapy candidate, ALKS 4230, in the